Dilek Azkur
Dilek Azkur has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Can Naci Kocabaş
Division of Pediatric Allergy and Immunology, Department of Children's Health and Diseases, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey
7 shared publications - Ahmet Kursat Azkur
Department of Virology, Faculty of Veterinary Medicine Kirikkale University Kirikkale Turkey
6 shared publications - Emine Vezir
Department of Pediatrics, Division of Allergy and Clinical Immunology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Türkiye
6 shared publications Ersoy Civelek
6 shared publications- Ayşenur Kaya
Department of Pediatric Allergy and Immunology, Ankara Children's Hematology Oncology Training and Research Hospital, Ankara, Turkey
5 shared publications - Cezmi A. Akdis
Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich Davos Switzerland
5 shared publications
Latest Publications
- 20 February 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (suppl1) , 74-76
Clinical characteristics of four children with azygos lobe: A Case Report
Introduction Normally, the azygos vein is localized in the posterior part of the upper lobe of the right lung. Still, during the process of embryogenesis, the azygos vein passes through the upper lobe of the lung. As a result of the parietal and visceral pleura being pulled together during this process, the azygos lobe is formed. The clinical features of the azygos lobe in children have not been summarized so far. Case Presentation This paper describes the presence of an azygos lobe in 4 pediatric patients presenting with cough and/or wheezing. Additionally, no pathological conditions such as bronchiectasis, pneumothorax, or neoplasm associated with the azygos lobe were observed in the evaluated patient series. Conclusion The azygos lobe does not require specific treatment unless it leads to clinically significant disease. However, to prevent misdiagnosis in radiological evaluations, clinicians should consider this anatomical variation.
- 20 February 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (suppl1) , 74-76
Clinical characteristics of four children with azygos lobe: A Case Report
Introduction Normally, the azygos vein is localized in the posterior part of the upper lobe of the right lung. Still, during the process of embryogenesis, the azygos vein passes through the upper lobe of the lung. As a result of the parietal and visceral pleura being pulled together during this process, the azygos lobe is formed. The clinical features of the azygos lobe in children have not been summarized so far. Case Presentation This paper describes the presence of an azygos lobe in 4 pediatric patients presenting with cough and/or wheezing. Additionally, no pathological conditions such as bronchiectasis, pneumothorax, or neoplasm associated with the azygos lobe were observed in the evaluated patient series. Conclusion The azygos lobe does not require specific treatment unless it leads to clinically significant disease. However, to prevent misdiagnosis in radiological evaluations, clinicians should consider this anatomical variation.
- Open Access
- 28 April 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (5) , 1
Correction to: Evaluation of drug-related anaphylaxis in children: multi-center study
- 28 April 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (5) , 1
Open AccessCorrection to: Evaluation of drug-related anaphylaxis in children: multi-center study
- 7 March 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (3) , 1-11
Evaluation of drug-related anaphylaxis in children: multi-center study
The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.1% (n 141) were female, were included. The median age of patients during the index episode was 107 months (IQR 56.5–161.5). Anaphylaxis occurred most frequently within hospital settings (62.1%, n 182) compared to home environments (34.1%, n 100). The administration were peroral in 40.3% (n 118), parenteral in 59.7% (n 175) of the cases. While antibiotics (56.7%), non-steroidal anti-inflammatory drugs (25.7%), and chemotherapeutics (3.4%) were the most commonly suspected drug groups, the cephalosporin group, and especially ceftriaxone (27.5% [n 80]) were the leading culprits among antibiotics. The anaphylaxis severity was severe in 39.6% (n 116), and moderate in 54.9% (n 161) of episodes. A biphasic reaction occurred in five patients. Only 72% (n 213) of patients were given adrenaline treatment. There were no fatalities. Diagnostic tests (n 64), including skin prick, intradermal, and drug provocation tests, which were performed between 1 and 120 months after the index reaction, yielded positive results in 23.4% (n 15), 17.2% (n 11), and 20.3% (n 13) of cases respectively, giving a total confirmation of 39 patients. Four patients underwent suspected drug desensitisation protocols. There were no fatalities. Conclusions: Antibiotics, particularly ceftriaxone, were the most commonly implicated agents in paediatric drug-induced anaphylaxis. Non-steroidal anti-inflammatory drugs, particularly ibuprofen, constituted the second most frequently implicated drug group. Paediatric patients experiencing drug-related anaphylaxis warrant algorithmic evaluation to ensure accurate diagnosis, prevent recurrence, and identify safe alternative treatments. What is Known: • Antibiotics, particularly ceftriaxone were the most frequently implicated culprit drugs, followed by NSAIDs, with ibuprofen being the most common within this group. What is New: • To the best of our knowledge, this is the largest multicenter paediatric drug-related anaphylaxis study, involving a large number of patients who evaluated by paediatric allergist. • We propose paediatric patients who experience drug induced anaphylaxis should undergo evaluation at specialized centres, to ensure accurate diagnosis, to prevent recurrence and identify safe alternative treatments.
- 7 March 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (3) , 1-11
Evaluation of drug-related anaphylaxis in children: multi-center study
The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.1% (n 141) were female, were included. The median age of patients during the index episode was 107 months (IQR 56.5–161.5). Anaphylaxis occurred most frequently within hospital settings (62.1%, n 182) compared to home environments (34.1%, n 100). The administration were peroral in 40.3% (n 118), parenteral in 59.7% (n 175) of the cases. While antibiotics (56.7%), non-steroidal anti-inflammatory drugs (25.7%), and chemotherapeutics (3.4%) were the most commonly suspected drug groups, the cephalosporin group, and especially ceftriaxone (27.5% [n 80]) were the leading culprits among antibiotics. The anaphylaxis severity was severe in 39.6% (n 116), and moderate in 54.9% (n 161) of episodes. A biphasic reaction occurred in five patients. Only 72% (n 213) of patients were given adrenaline treatment. There were no fatalities. Diagnostic tests (n 64), including skin prick, intradermal, and drug provocation tests, which were performed between 1 and 120 months after the index reaction, yielded positive results in 23.4% (n 15), 17.2% (n 11), and 20.3% (n 13) of cases respectively, giving a total confirmation of 39 patients. Four patients underwent suspected drug desensitisation protocols. There were no fatalities. Conclusions: Antibiotics, particularly ceftriaxone, were the most commonly implicated agents in paediatric drug-induced anaphylaxis. Non-steroidal anti-inflammatory drugs, particularly ibuprofen, constituted the second most frequently implicated drug group. Paediatric patients experiencing drug-related anaphylaxis warrant algorithmic evaluation to ensure accurate diagnosis, prevent recurrence, and identify safe alternative treatments. What is Known: • Antibiotics, particularly ceftriaxone were the most frequently implicated culprit drugs, followed by NSAIDs, with ibuprofen being the most common within this group. What is New: • To the best of our knowledge, this is the largest multicenter paediatric drug-related anaphylaxis study, involving a large number of patients who evaluated by paediatric allergist. • We propose paediatric patients who experience drug induced anaphylaxis should undergo evaluation at specialized centres, to ensure accurate diagnosis, to prevent recurrence and identify safe alternative treatments.
- Open Access
- 24 December 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (3) , 377-380
ÇOCUKLARDA ANAFİLAKSİNİN NADİR BİR SEBEBİ: TAVUK ETİ ALERJİSİ
Tavuk eti, dünya genelinde yaygın olarak tüketilen bir besin olmasıyla birlikte, nadir durumlarda IgE aracılı alerjik reaksiyonlara ve anafilaksiye yol açabilir. Tavuk eti alerjisi, doğrudan birincil bir alerji olabileceği gibi, yumurta-kuş sendromu veya balık-tavuk sendromu gibi çapraz reaksiyonlara bağlı ikincil bir alerji olarak da ortaya çıkabilir. Bu makalede, birincil tavuk eti alerjisine bağlı tekrarlayan anjiyoödem ve anafilaksi öyküsü olan 17 yaşında bir adolesan olgu sunulmaktadır. Olgunun öyküsünden son dört yıldır tekrarlayan ajiyoödeminin olduğu, tavuk eti tüketimi sonrası dudaklarda şişlik, kızarıklık, nefes darlığı ve karın ağrısı gibi semptomlar ile acil servise başvurusu olduğu öğrenilmiştir. Diğer besinlerle semptom tariflemeyen hastanın deri prik testinde tavuk eti, hindi eti ve kedi tüyüne duyarlılık saptanmış, ancak yumurta veya balık alerjisi bulunmamıştır. Klinik ve laboratuvar değerlendirmeler sonucunda, tavuk etine bağlı birincil alerji tanısı konulmuş ve hastaya çapraz reaksiyon riski nedeniyle tavuk eti ve diğer kümes hayvanlarının etlerini tüketmemesi önerilmiştir. Sonuç olarak, birincil tavuk eti alerjisi nadir görülen bir durum olsa da tekrarlayan anjiyoödem ve anafilaksi vakalarında tavuk etinin olası bir tetikleyici olduğu göz önünde bulundurulmalıdır.
- 24 December 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (3) , 377-380
Open AccessÇOCUKLARDA ANAFİLAKSİNİN NADİR BİR SEBEBİ: TAVUK ETİ ALERJİSİ
Tavuk eti, dünya genelinde yaygın olarak tüketilen bir besin olmasıyla birlikte, nadir durumlarda IgE aracılı alerjik reaksiyonlara ve anafilaksiye yol açabilir. Tavuk eti alerjisi, doğrudan birincil bir alerji olabileceği gibi, yumurta-kuş sendromu veya balık-tavuk sendromu gibi çapraz reaksiyonlara bağlı ikincil bir alerji olarak da ortaya çıkabilir. Bu makalede, birincil tavuk eti alerjisine bağlı tekrarlayan anjiyoödem ve anafilaksi öyküsü olan 17 yaşında bir adolesan olgu sunulmaktadır. Olgunun öyküsünden son dört yıldır tekrarlayan ajiyoödeminin olduğu, tavuk eti tüketimi sonrası dudaklarda şişlik, kızarıklık, nefes darlığı ve karın ağrısı gibi semptomlar ile acil servise başvurusu olduğu öğrenilmiştir. Diğer besinlerle semptom tariflemeyen hastanın deri prik testinde tavuk eti, hindi eti ve kedi tüyüne duyarlılık saptanmış, ancak yumurta veya balık alerjisi bulunmamıştır. Klinik ve laboratuvar değerlendirmeler sonucunda, tavuk etine bağlı birincil alerji tanısı konulmuş ve hastaya çapraz reaksiyon riski nedeniyle tavuk eti ve diğer kümes hayvanlarının etlerini tüketmemesi önerilmiştir. Sonuç olarak, birincil tavuk eti alerjisi nadir görülen bir durum olsa da tekrarlayan anjiyoödem ve anafilaksi vakalarında tavuk etinin olası bir tetikleyici olduğu göz önünde bulundurulmalıdır.
- Open Access
- 20 August 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (2) , 207-213
EOZİNOFİLİ SAPTANAN ÇOCUK VAKALARDA ETİYOLOJİK FAKTÖRLERİN DEĞERLENDİRİLMESİ
Amaç: Eozinofili dokularda ve/veya kanda eozinofillerin artması olarak tanımlanır. Periferik kanda eozinofil sayısının artması alerjik, enfeksiyöz, otoimmün ve malign hastalıkların ayırıcı bir özelliği ya da eşlik eden bulgusu olabilir. Çalışmamızda eozinofilisi olan çocuk hastaların etiyolojik faktörler açısından taranması amaçlanmıştır. Gereç ve Yöntemler: Kırıkkale Üniversitesi Tıp Fakültesi Çocuk Alerji ve İmmünoloji Polikliniğine Şubat 2020-Kasım 2021 tarihleri arasında başvuran ve tam kan sayımında eozinofili saptanan 1 ay-18 yaş arasındaki tüm hastaların elektronik dosyaları geriye dönük olarak incelendi. Tam kan sayımı ölçümünde periferik kan mutlak eozinofil sayısı ≥500 hücre/μL olması eozinofili olarak kabul edildi. Hastaların demografik verileri, klinik bulguları ve tetkik sonuçları retrospektif olarak değerlendirildi. Bulgular: Çalışmaya dahil edilen 176 hastanın 104’ü (%59.1) erkek olup, ortanca yaş 4.1 (0.6-8.9) [ortanca (çeyrekler arası aralık)] yıl idi. Hastaların 68’inde (%38.6) alerjik rinit, 51’inde (%28.9) atopik dermatit, 44’ünde (%25.0) astım ve 41’inde (%23.2) besin alerjisi vardı. Deri prik testi yapılan 113 hastanın 72’sinde (%63.7) alerjik duyarlanma saptandı. Alerjik duyarlanma saptanan hastalarda en sık polen (%43.0) ve besin duyarlılığı (%45.8) olduğu görüldü. Laboratuvar tetkiklerinde ortanca eozinofil sayısı 720/μL (580-1050), total IgE düzeyi 99.0 IU/mL (20.8-272) saptandı. Hastaların 25’inde (%14.2) en az bir immünglobülin düzeyinde düşüklük saptandı. Üç hastada (%1.7) paraziter hastalık mevcuttu. Sonuç: Alerjik hastalıklar eozinofilinin önemli nedeni olmakla birlikte paraziter hastalıklar, immün yetmezlikler gibi altta yatan birçok hastalıkta eozinofili görülebilir. Kapsamlı öykü ve klinik değerlendirme ayırıcı tanıda önemlidir.
- 20 August 2024
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 26 (2) , 207-213
Open AccessEOZİNOFİLİ SAPTANAN ÇOCUK VAKALARDA ETİYOLOJİK FAKTÖRLERİN DEĞERLENDİRİLMESİ
Amaç: Eozinofili dokularda ve/veya kanda eozinofillerin artması olarak tanımlanır. Periferik kanda eozinofil sayısının artması alerjik, enfeksiyöz, otoimmün ve malign hastalıkların ayırıcı bir özelliği ya da eşlik eden bulgusu olabilir. Çalışmamızda eozinofilisi olan çocuk hastaların etiyolojik faktörler açısından taranması amaçlanmıştır. Gereç ve Yöntemler: Kırıkkale Üniversitesi Tıp Fakültesi Çocuk Alerji ve İmmünoloji Polikliniğine Şubat 2020-Kasım 2021 tarihleri arasında başvuran ve tam kan sayımında eozinofili saptanan 1 ay-18 yaş arasındaki tüm hastaların elektronik dosyaları geriye dönük olarak incelendi. Tam kan sayımı ölçümünde periferik kan mutlak eozinofil sayısı ≥500 hücre/μL olması eozinofili olarak kabul edildi. Hastaların demografik verileri, klinik bulguları ve tetkik sonuçları retrospektif olarak değerlendirildi. Bulgular: Çalışmaya dahil edilen 176 hastanın 104’ü (%59.1) erkek olup, ortanca yaş 4.1 (0.6-8.9) [ortanca (çeyrekler arası aralık)] yıl idi. Hastaların 68’inde (%38.6) alerjik rinit, 51’inde (%28.9) atopik dermatit, 44’ünde (%25.0) astım ve 41’inde (%23.2) besin alerjisi vardı. Deri prik testi yapılan 113 hastanın 72’sinde (%63.7) alerjik duyarlanma saptandı. Alerjik duyarlanma saptanan hastalarda en sık polen (%43.0) ve besin duyarlılığı (%45.8) olduğu görüldü. Laboratuvar tetkiklerinde ortanca eozinofil sayısı 720/μL (580-1050), total IgE düzeyi 99.0 IU/mL (20.8-272) saptandı. Hastaların 25’inde (%14.2) en az bir immünglobülin düzeyinde düşüklük saptandı. Üç hastada (%1.7) paraziter hastalık mevcuttu. Sonuç: Alerjik hastalıklar eozinofilinin önemli nedeni olmakla birlikte paraziter hastalıklar, immün yetmezlikler gibi altta yatan birçok hastalıkta eozinofili görülebilir. Kapsamlı öykü ve klinik değerlendirme ayırıcı tanıda önemlidir.
- Open Access
Recent developments in the immunopathology of COVID‐19
There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID‐19. The efficacy of the COVID‐19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID‐19 vaccines have changed the clinical scenario of COVID‐19. Multisystem inflammatory syndrome in children (MIS‐C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long‐term symptoms of COVID‐19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID‐19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID‐19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID‐19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID‐19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID‐19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS‐CoV‐2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high‐risk groups, the development of MIS‐C and long COVID‐19.
Open AccessRecent developments in the immunopathology of COVID‐19
There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID‐19. The efficacy of the COVID‐19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID‐19 vaccines have changed the clinical scenario of COVID‐19. Multisystem inflammatory syndrome in children (MIS‐C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long‐term symptoms of COVID‐19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID‐19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID‐19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID‐19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID‐19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID‐19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS‐CoV‐2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high‐risk groups, the development of MIS‐C and long COVID‐19.
- Open Access
- 21 September 2021
- Published by Wiley in Clinical and Translational Allergy
- Vol. 11 (7) , e12065
Recent advances and developments in COVID‐19 in the context of allergic diseases
Background: Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma.Methods: Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed.Results and Conclusions: In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
- 21 September 2021
- Published by Wiley in Clinical and Translational Allergy
- Vol. 11 (7) , e12065
Open AccessRecent advances and developments in COVID‐19 in the context of allergic diseases
Background: Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma.Methods: Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed.Results and Conclusions: In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.
- Top Cited PapersOpen Access
Risk factors for severe and critically ill COVID‐19 patients: A review
The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID‐19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID‐19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high‐sensitivity C‐reactive protein, proinflammatory cytokines such as interleukin (IL)‐6, IL‐1β, Krebs von den Lungen‐6 (KL‐6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID‐19.
Top Cited PapersOpen AccessRisk factors for severe and critically ill COVID‐19 patients: A review
The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID‐19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID‐19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high‐sensitivity C‐reactive protein, proinflammatory cytokines such as interleukin (IL)‐6, IL‐1β, Krebs von den Lungen‐6 (KL‐6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID‐19.
- Open Access
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.
Open AccessA compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.